Provided by Tiger Trade Technology Pte. Ltd.

Rocket Pharmaceuticals, Inc.

3.31
-0.1250-3.64%
Volume:1.48M
Turnover:5.07M
Market Cap:357.67M
PE:-1.48
High:3.57
Open:3.45
Low:3.29
Close:3.43
52wk High:13.35
52wk Low:2.19
Shares:108.22M
Float Shares:78.79M
Volume Ratio:0.51
T/O Rate:1.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2397
EPS(LYR):-2.7292
ROE:-74.88%
ROA:-40.56%
PB:1.14
PE(LYR):-1.21

Loading ...

Rocket Pharmaceuticals Appoints Martin Wilson as Interim Principal Financial Officer Following Aaron Ondrey's Resignation

Reuters
·
Aug 26

Rocket Pharmaceuticals Inc : Bofa Global Research Raises to Buy From Neutral; Raises Price Objective to $10 From $4

THOMSON REUTERS
·
Aug 21

John Militello, Officer, Reports Disposal of Common Shares in Rocket Pharmaceuticals Inc

Reuters
·
Aug 21

BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, silver miners, oil firms

Reuters
·
Aug 21

Rocket Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 21

Rocket Pharmaceuticals Up Over 17%, on Pace for Largest Percent Increase Since September 2023 -- Data Talk

Dow Jones
·
Aug 20

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. -- Barrons.com

Dow Jones
·
Aug 20

Rocket Pharmaceuticals Shares up 34.9% After US FDA Lifts Clinical Hold on Co's Gene Therapy Trial

THOMSON REUTERS
·
Aug 20

FDA Lifts Clinical Hold on Rocket Pharmaceuticals' Phase 2 Trial for Danon Disease Treatment

Reuters
·
Aug 20

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of Rp-a501 for the Treatment of Danon Disease

THOMSON REUTERS
·
Aug 20

Rocket Pharmaceuticals Inc - FDA Authorizes Study Resumption With Recalibrated Dose

THOMSON REUTERS
·
Aug 20

Rocket Pharmaceuticals- to Work With Investigators to Implement Immunomodulatory Regimen More Closely Reflecting Given in Phase 1 Pediatric Cohort

THOMSON REUTERS
·
Aug 20

Jonathan David Schwartz, Chief Medical & Gene Therapy Officer, Reports Disposal of Rocket Pharmaceuticals Inc. Common Shares

Reuters
·
Aug 19

Rocket Pharmaceuticals Q2 EPS $(0.62) Misses $(0.56) Estimate

Benzinga
·
Aug 08

BRIEF-Rocket Pharmaceuticals Q2 Basic EPS USD -0.62

Reuters
·
Aug 08

Rocket Pharmaceuticals Reports Q2 2025 Results; No Significant Variations in Sales, Net Income, or EPS Announced

Reuters
·
Aug 08

Rocket Pharmaceuticals Inc - to Reduce Headcount by 30% and Cash Burn by 25%

THOMSON REUTERS
·
Aug 08

Rocket Pharmaceuticals Inc - Investigation Into Sae From Rp-a501 Phase 2 Study Ongoing

THOMSON REUTERS
·
Aug 08

Rocket Pharmaceuticals Inc - FDA Fast Track Designation Received for Rp-a701 in Bag3-Dcm

THOMSON REUTERS
·
Aug 08

Top FDA Official's Surprise Departure Means More Uncertainty for Biotech -- Barrons.com

Dow Jones
·
Jul 31